HomeCompareABT vs SYK

ABT vs SYK: Dividend Comparison 2026

ABT yields 2.36% · SYK yields 1.04%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABT wins by $490.3K in total portfolio value
10 years
ABT
ABT
● Live price
2.36%
Share price
$101.89
Annual div
$2.40
5Y div CAGR
63.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$533.6K
Annual income
$328,772.04
Full ABT calculator →
SYK
SYK
● Live price
1.04%
Share price
$326.10
Annual div
$3.40
5Y div CAGR
46.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$43.3K
Annual income
$8,282.98
Full SYK calculator →

Portfolio growth — ABT vs SYK

📍 ABT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodABTSYK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ABT + SYK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ABT pays
SYK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ABT
Annual income on $10K today (after 15% tax)
$200.23/yr
After 10yr DRIP, annual income (after tax)
$279,456.23/yr
SYK
Annual income on $10K today (after 15% tax)
$88.62/yr
After 10yr DRIP, annual income (after tax)
$7,040.53/yr
At 15% tax rate, ABT beats the other by $272,415.70/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ABT + SYK for your $10,000?

ABT: 50%SYK: 50%
100% SYK50/50100% ABT
Portfolio after 10yr
$288.5K
Annual income
$168,527.51/yr
Blended yield
58.42%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SYK right now

ABT
Analyst Ratings
30
Buy
10
Hold
Consensus: Buy
Price Target
$137.67
+35.1% upside vs current
Range: $120.00 — $158.00
Altman Z
4.9
Piotroski
6/9
SYK
Analyst Ratings
1
Strong
35
Buy
14
Hold
Consensus: Buy
Price Target
$428.67
+31.5% upside vs current
Range: $390.00 — $469.00
Altman Z
4.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ABT buys
0
SYK buys
0
No recent congressional trades found for ABT or SYK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricABTSYK
Forward yield2.36%1.04%
Annual dividend / share$2.40$3.40
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR63.2%46.2%
Portfolio after 10y$533.6K$43.3K
Annual income after 10y$328,772.04$8,282.98
Total dividends collected$492.4K$21.0K
Payment frequencyquarterlyquarterly
SectorHealthcareHealthcare
Analyst consensusBuyBuy
Analyst price target$137.67$428.67

Year-by-year: ABT vs SYK ($10,000, DRIP)

YearABT PortfolioABT Income/yrSYK PortfolioSYK Income/yrGap
1← crossover$11,084$384.43$10,852$152.43+$232.00ABT
2$12,510$649.94$11,838$226.03+$672.00ABT
3$14,505$1,118.82$13,004$336.89+$1.5KABT
4$17,499$1,978.53$14,420$505.63+$3.1KABT
5$22,364$3,640.59$16,195$766.09+$6.2KABT
6$31,026$7,096.70$18,504$1,175.64+$12.5KABT
7$48,215$15,016.56$21,635$1,835.40+$26.6KABT
8$87,182$35,592.30$26,082$2,932.10+$61.1KABT
9$191,446$98,161.15$32,737$4,829.68+$158.7KABT
10$533,619$328,772.04$43,312$8,282.98+$490.3KABT

ABT vs SYK: Complete Analysis 2026

ABTHealthcare

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Full ABT Calculator →

SYKHealthcare

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.

Full SYK Calculator →
📬

Get this ABT vs SYK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ABT vs SCHDABT vs JEPIABT vs OABT vs KOABT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.